21.01.2021

Blueberries Medical Closes $1M Strategic Financing Led by a Leading Latin American Private Equity Group with Extensive International Cannabis Industry Expertise; Appoints Facundo Garretón as Chairman & Interim CEO

Toronto, Ontario (January 20, 2021) – Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the completion of a non-brokered private placement for aggregate gross proceeds of C$1,000,000 (the “Offering”) from the sale of common shares (“Common Shares”) at a price of C$0.065 per Common Share. 

07.12.2020

Blueberries Medical Announces Closing of the Acquisition of BBV Labs – A Milestone in its Argentina Project

Toronto, Ontario (December 4, 2020) – Further to its news releases dated March 26, April 4, and July 2, 2019, Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products is pleased to announce that the Company has completed the acquisition of BBV Labs Inc. (“BBV”), a corporation formed under the laws of the Republic of Panama, pursuant to the previously announced share purchase agreement (the “Purchase Agreement”). 

07.12.2020

Blueberries Medical Announces Closing of the Acquisition of BBV Labs – A Milestone in its Argentina Project

 

Toronto, Ontario (December 4, 2020) – Further to its news releases dated March 26, April 4, and July 2, 2019, Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products is pleased to announce that the Company has completed the acquisition of BBV Labs Inc. (“BBV”), a corporation formed under the laws of the Republic of Panama, pursuant to the previously announced share purchase agreement (the “Purchase Agreement”).

03.12.2020

Blueberries is pleased to share its operating and financial results for the three and nine months ended September 30, 2020, as filed on SEDAR:

HIGHLIGHTS

  • Earlier this year, Blueberries implemented extensive cost saving measures of reducing administrative, capital, and operational expenditures and preserving working capital to optimize its cost structure and focus on revenue bringing activities.
  • Due to the ongoing impact of the coronavirus (“COVID-19”) pandemic, Blueberries is continuing its cost saving measures until significant revenues from sales commence.
  • On September 10, 2020 Camilo Villalba, Co-founder & Chief Executive Officer (“CEO”), presented live at VirtualInvestorConferences.com.
08.09.2020

Blueberries Medical to Webcast Live at VirtualInvestorConferences.com on September 10th

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Blueberries Medical Corp.

10.07.2020

BBM - Information Circular 2020

BLUBERRIES MEDICAL CORP.
Notice of Annual General and Special Meeting of Shareholders
June 24, 2020
Management Information Circular

See more

10.07.2020

Sedar Return Card

Under securities regulations, a reporting issuer must send annually a form to holders to request the Interim Financial Statements
and MD&A and/or the Annual Financial Statements and MD&A. If you would like to receive the report(s) by mail, please make
your selection and return to the address as noted or register online at www.computershare.com/mailinglist.

09.06.2020

Blueberries Announces Strategic Partnership with medcann

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce  that its wholly-owned subsidiary Blueberries SAS entered into a collaboration agreement (the "Partnership") with Medicamentos de Cannabis SAS (“medcann”), to develop, and produce Tetrahydrocannabinol (“THC”) cannabis extracts for the international market.

02.06.2020

Blueberries Commences Commercial Sales of Proprietary Cultivars to Local Partners

Toronto, Ontario (June 2, 2020) – Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that it has officially commenced sales of its proprietary cultivars approved by the Colombian Institute of Agriculture (“ICA”). 

11.05.2020

Blueberries Medical to export cannabis oil from Colombia into the US market in 3Q of this year

Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) CFO Ian Atacan tells Proactive the Toronto-headquartered medical cannabis producer with operations in Colombia will be entering the US market by way of its joint venture with Colombia-based QualCann SAS.

Subscribe to Media